Literature DB >> 17171384

[Pain therapy with antipyretic analgesics].

B Hinz1, K Brune.   

Abstract

The pharmacotherapy of musculoskeletal pain remains of high importance in Western countries. The present review concentrates on the use of acidic (nonsteroidal anti-inflammatory drugs) and nonacidic (paracetamol, selective cyclooxygenase-2 inhibitors) antipyretic analgesics in the therapy of musculoskeletal pain disorders with particular emphasis on the diverse pharmacokinetic properties and unwanted side effects of these substances.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17171384     DOI： 10.1007/s00132-006-1024-9

Source DB:  PubMed          Journal:  Orthopade        ISSN： 0085-4530            Impact factor:   1.087


  47 in total

1.  Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.

Authors:  Pär Gyllfors; Grazyna Bochenek; John Overholt; Diane Drupka; Maria Kumlin; James Sheller; Ewa Nizankowska; Peter C Isakson; Filip Mejza; James B Lefkowith; Sven-Erik Dahlén; Andrew Szczeklik; John J Murray; Barbro Dahlén
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

Review 2.  Selective cyclooxygenase-2 inhibitors: similarities and differences.

Authors:  K Brune; B Hinz
Journal:  Scand J Rheumatol       Date:  2004       Impact factor: 3.641

3.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

4.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

6.  Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins.

Authors:  Kerstin Rabausch; Ellen Bretschneider; Mario Sarbia; Jutta Meyer-Kirchrath; Petra Censarek; Robert Pape; Jens W Fischer; Karsten Schrör; Artur-Aron Weber
Journal:  Circ Res       Date:  2004-12-09       Impact factor: 17.367

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation.

Authors:  F Beiche; S Scheuerer; K Brune; G Geisslinger; M Goppelt-Struebe
Journal:  FEBS Lett       Date:  1996-07-22       Impact factor: 4.124

9.  Non-narcotic analgesic dose and risk of incident hypertension in US women.

Authors:  John P Forman; Meir J Stampfer; Gary C Curhan
Journal:  Hypertension       Date:  2005-08-15       Impact factor: 10.190

10.  GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization.

Authors:  Robert J Harvey; Ulrike B Depner; Heinz Wässle; Seifollah Ahmadi; Cornelia Heindl; Heiko Reinold; Trevor G Smart; Kirsten Harvey; Burkhard Schütz; Osama M Abo-Salem; Andreas Zimmer; Pierrick Poisbeau; Hans Welzl; David P Wolfer; Heinrich Betz; Hanns Ulrich Zeilhofer; Ulrike Müller
Journal:  Science       Date:  2004-05-07       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.